Development of Oral Tablet Formulation Containing Erlotinib: Randomly Methylated-β-cyclodextrin Inclusion Complex Using Direct Compression Method

Abstract

These results demonstrate that a new tablet formulation of ERL: RAMEB-CD inclusion complex could be an alternative approach to achieve increased dissolution and oral bioavailability of ERL for NSCLC treatment.